Spero Therapeutics SPRO 深 滬
等待開盤 09-30 09:30:00 美东时间
1.90
+0.010
+0.53%
華盛通- 最 高1.934
- 今 開1.89
- 成交量 15.87万股
- 最 低 1.88
- 昨 收 1.89
- 總市值 1.06亿
- 52周最高 3.22
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 0.5052
- 委 比 20.05%
- 總股本 5591.06万
- 歷史最高 23.639
- 量 比 0.55
- 振 幅 2.86%
- 歷史最低 0.5052
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Red Cat Collaborates with Safe Pro Group to Embed Real-Time AI-Powered Threat Detection Onboard the Black Widow™ Drone Platform
Red Cat Holdings, Inc. and Safe Pro Group Inc. announce a strategic collaboration to integrate Safe Pro's AI-powered threat detection technology into Red Cat's Black Widow drones. This integration enhances the drones' ability to detect explosive threats in real-time, improving situational awareness and decision-making for military operations. The collaboration leverages Safe Pro's advanced systems to process drone imagery and share critical data,...
09-15 12:00
Perspective Therapeutics Names Joel Sendek CFO As Juan Graham Departs
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as
09-04 19:24
Spero Therapeutics Q2 EPS $(0.03) Beats $(0.38) Estimate, Sales $14.189M Up From $10.197M YoY
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.38) by 92.11 percent. This is a 90.91 percent increase over losses of $(0.33) per share
08-13 04:03
Here are the major earnings after the close Tuesday
Major earnings expected after the bell on Tuesday include: CoreWeave (CRWV) Inovio Pharmaceuticals (INO) Luminar Technologies (LAZR) Lumentum Holdings (LITE) Gladstone Investment Corporation (GAIN) Ot...
08-12 22:00
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
Spero Therapeutics announced the early termination of its Phase 3 PIVOT-PO trial for tebipenem HBr in treating complicated urinary tract infections (cUTI) due to demonstrated efficacy. The company plans to submit trial data to the FDA by mid-2025. Financially, Spero reported a net loss of $1.7 million for Q2 2025, with collaboration revenue from GSK contributing significantly. The company anticipates sufficient funding through 2028. Tebipenem HBr...
08-12 20:01
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Earnings Outlook For Spero Therapeutics
Spero Therapeutics (NASDAQ:SPRO) is set to give its latest quarterly earnings r...
08-12 03:03
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
<p>Spero Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections, will hold a conference call and live webcast on August 12, 2025, at 4:30 p.m. ET to discuss second quarter 2025 financial results and provide a business update. The call can be accessed via phone or webcast with specific details provided, and an archived version will be available on the company's web...
08-05 20:05
Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.
Shares of several biotechnology stocks are trading higher amid Vinay Prasad's d...
07-31 02:12
企业管理软件哪个好用？ERP系统软件功能亮点推荐！
在工业 4.0 与全球供应链重构的背景下，企业资源计划（ERP）系统正经历从 “流程记录工具” 到 “智能决策中枢” 的根本性变革。随着制造业向智能化、绿色化转...
07-21 15:51
